What are the 4 stages of rheumatoid arthritis?

Short answer

Rheumatoid arthritis is often described in four stages: Stage 1, early inflammation of the joint lining with no visible bone damage yet; Stage 2, inflammation starting to damage the cartilage; Stage 3, damage reaching the bone with erosion, deformity and lost function; and Stage 4, end-stage, where the joint may fuse and inflammation can quiet down but the damage is permanent. The crucial part most lists leave out: this is not a countdown you are doomed to complete. Having the disease is not your fault, the fear the stage lists provoke is not irrational, and — most importantly — treatment started early can stop the progression. Many people never move past the first stages.

Note: this article explains the four-stage framework and is not medical advice. Only a rheumatologist can assess your disease activity and stage; RA is treatable, and early treatment can stop the progression described below.

The stages are a map, not a sentence

If you have just been diagnosed and searched "stages of rheumatoid arthritis", the four-stage picture can read like a countdown to disability. The fear is understandable and it is not overblown of you to feel it — but it is not your future written down, and that is worth saying plainly before the details. The stages describe what untreated or under-treated RA can do over time, not what will happen to you. Modern treatment changed this disease. Started early, disease-modifying drugs can halt progression, and Cleveland Clinic notes outright that it may take many years to move through the stages and that some people never progress through all of them.

So read the stages as a map of what the disease is capable of and why doctors push to treat it fast — not as your personal timeline. The single most useful thing the stages teach is why the early window matters so much.

The four stages

Stage 1 — early RA: inflammation, no damage yet

This is where it begins, in the synovium — the thin lining inside the joint. The immune system attacks it, the lining becomes inflamed and swollen, and you feel the classic early signs: joint pain, stiffness (especially long morning stiffness), and tenderness, often in the small joints of the hands and feet. On an X-ray at this stage, there is usually no bone damage yet. That is the point of catching it here: the inflammation is active, but the joint is still structurally intact. This is the stage where treatment has the most to protect.

Stage 2 — moderate RA: the cartilage starts to suffer

If the inflammation continues, it begins to damage cartilage — the smooth cushion on the ends of the bones. Pain and stiffness typically increase, range of movement starts to narrow, and the joints may swell more persistently. The damage is no longer only "inflammation you feel"; it is starting to become "structure you lose". Treatment still has a great deal to protect here, because bone has not yet been eroded.

Stage 3 — severe RA: damage reaches the bone

Now the process extends past cartilage into bone. Erosion appears, joints can begin to deform, and the loss of cartilage plus bone damage means more pain, more visible change in the joints — especially the hands — and a real drop in function. Grip weakens; joints may drift out of alignment. This is the stage the four-stage lists are warning about, and it is precisely what early treatment is designed to prevent reaching.

Stage 4 — end-stage RA: the joint stops working

In the final stage, the joint may fuse — a process called ankylosis — and stop moving altogether. Paradoxically, the active inflammation can quieten at this point, but that is not recovery: the joint damage is permanent, and function is severely limited. Reaching this stage is far less common now than it once was, precisely because treatment intervenes long before, but it is the reason the disease is taken so seriously.

What the stages feel like in the hands

Because RA so often starts in the hands, it helps to translate the stages into what people actually notice there — not to self-stage, but to recognise change worth reporting.

Early on, the knuckles and the middle joints of the fingers feel stiff and tender, worst in the morning, and making a fist can take longer than it used to. Nothing looks dramatically wrong, and the joints still work — this is exactly when the disease is most worth catching, and exactly when it is easiest to dismiss as "I must have overused my hands".

As inflammation continues, the swelling becomes more persistent rather than just morning stiffness, grip weakens, and everyday hand tasks — opening jars, turning keys, buttoning, holding a phone — start to cost real effort. This is the shift from "stiffness I feel" to "strength I have lost", and it is the signal to make sure treatment is actually controlling the inflammation.

Later, if the process has reached bone, the joints can visibly change — knuckles enlarging, fingers drifting out of line — and function drops in a way that is hard to miss. By this point the goal of care has shifted toward protecting what remains and managing the damage already done.

The reason to know this is not to place yourself on the ladder but to notice movement along it: hands that are getting stiffer for longer, or losing strength month over month, are telling you the inflammation is not controlled — and that is a conversation to have before the next stage, not after. A single stiff morning is nothing to act on; a clear trend across several weeks is. That distinction — one bad day versus a direction of travel — is exactly the thing your own records are good at showing, and it is what turns a vague worry into something a rheumatologist can act on.

Why the stages matter less than the clock

Here is the part rheumatologists care about more than the stage number. Joint damage in RA can begin early — erosion and cartilage destruction may be visible within the first two years — and once that damage happens, it generally cannot be reversed. That is why there is such urgency about the first months rather than about which stage you are "in".

In practice, rheumatologists do not treat by rigid stages at all. They track disease activity — how active the inflammation is right now, using measures like the DAS28 score — and adjust treatment toward a target of remission or low activity, a strategy called treat-to-target. Under national guidance, disease activity is reassessed regularly and medication is stepped up until the inflammation is controlled. The goal is to keep you at Stage 1's level of joint integrity indefinitely, regardless of how long you have had the diagnosis.

So if you have RA, the useful questions are not "which stage am I?" but "how active is my inflammation, and is my treatment getting it to target?" The stage describes accumulated damage; disease activity describes what is happening now — and it is what is happening now that you can still change.

What your own data can add

Between appointments, the thing that drives progression — active inflammation, showing up as flares — is exactly what your everyday data can help you notice earlier.

In a 2025 study of people with RA wearing consumer devices, physiological metrics — resting and night-time heart rate, heart-rate-variability rhythm, and activity — shifted up to four weeks before a flare was consciously felt. An earlier activity-tracker study found flares showed up as a measurable drop in daily movement: when inflammation rises, people move less without deciding to. That matters for staging because uncontrolled flares are how the disease advances; catching them earlier means getting them treated before they add damage.

The reading only means something against your own baseline — "normal" is personal. In Welltory data from about 5,000 people who track with a wearable, resting heart rate alone spans the low 50s to the mid 70s, so no single number signals a flare; what matters is a shift away from your usual. Welltory measures heart rate, HRV, sleep and activity from your phone or watch, so a run-up — resting heart rate creeping up, sleep less restorative, steps falling as joints stiffen — becomes a record you can take to your rheumatologist instead of a half-remembered "it started a while ago". (These figures describe a tracking cohort skewing older, around 40–72, not the whole population — they show how wide the spread is, not a target.)

What it cannot do: tell you your stage, see inflammation or erosion in a joint, or replace the exam, bloods and imaging that stage and monitor RA. Its job is to help you catch the flares that drive progression a little sooner.

Why two people with the same diagnosis end up in very different places

One of the most confusing things after a diagnosis is meeting two people with "the same RA" whose lives look nothing alike — one barely troubled, one significantly disabled. The stages explain the outcome but not the reason, and the reason matters more.

Part of it is the disease itself: RA varies in how aggressive it is from person to person, and some people simply have a milder course. Part of it is how early it was caught and treated — the person diagnosed and started on treatment within weeks of symptoms has a very different trajectory from the person who waited two years while damage accumulated. And part of it is how well the inflammation has been controlled since, because it is the years of active, untreated flares that carry someone from one stage to the next.

There is also a recognised harder end of the spectrum, sometimes called difficult-to-treat RA, where inflammation resists the usual medications and needs a specialist to keep changing the approach. That is not the common case, and it is not something to assume about yourself — but it is why staying engaged with a rheumatologist matters even when things feel stable.

The practical point is hopeful rather than frightening: the biggest differences between those two people are the things that can still be influenced — how fast treatment started and how well inflammation is kept controlled — not a fixed severity you were handed at diagnosis.

What actually slows progression

The stages are driven by inflammation, so slowing them is about controlling inflammation — and that is mostly medical, with lifestyle supporting it rather than replacing it.

• Early disease-modifying treatment (DMARDs) is the single biggest lever. Started promptly, it is what keeps most people from moving past the early stages. This is a rheumatologist's call, not a lifestyle choice.

• Treat-to-target follow-up — regular disease-activity checks and stepping up treatment until inflammation is controlled — keeps the disease from quietly advancing between visits.

• Keeping the joints moving. Regular, individually adapted exercise maintains joint mobility, muscle strength and function; during a flare the load is reduced, but full immobility is not the goal.

• The cardiovascular and bone side. RA raises cardiovascular risk and affects bone health, so not smoking, staying active, and managing blood pressure and weight are part of RA care, not extras.

• Catching flares early. The sooner an active flare is treated, the less damage it can add — which is where tracking the run-up is genuinely useful.

When to contact your rheumatologist

• A flare that is not settling, or is worse or longer than your usual pattern.

• New joint swelling, or a joint starting to lose movement or change shape.

• Morning stiffness that has crept longer than your baseline over recent weeks.

• Fatigue, low-grade fever or feeling generally unwell alongside the joints — RA is systemic, and these can signal rising activity.

• Any new shortness of breath, chest symptoms, or eye pain and redness — RA can affect organs beyond the joints, and these need prompt attention.

How to bring this up with your doctor

Ask about activity, not just stage. A useful opening: "How active is my RA right now, and are we at target?" It steers the conversation to the thing that is still changeable rather than to a stage label.

Bring the run-up. Four to eight weeks of how your joints, morning stiffness and energy have behaved — and, if you track, whether your resting heart rate, sleep and activity shifted around the bad stretches. That helps show whether flares are being caught and controlled.

What to ask for.

• Whether your current treatment is controlling disease activity, or whether it should be stepped up under treat-to-target.

• If you were diagnosed recently: how quickly disease-modifying treatment should start, given that early treatment is what protects the joints.

• How your flares are being monitored between visits, and what should prompt you to come in sooner.

If progression worries you, it is fair to ask directly what is being done to prevent joint damage and how your response to treatment is being measured. In RA, that question is the point — the stages are only frightening when the inflammation is left to run.

How we made it

Written from clinical sources — Cleveland Clinic for the four-stage framework, NIAMS and Johns Hopkins Arthritis Center for progression and the early-damage timeline, Versus Arthritis and NRAS for disease-activity monitoring and treat-to-target — plus peer-reviewed wearable studies for the flare-and-physiology angle. Where the stages oversimplify, we say so: clinicians track disease activity rather than rigid stages.

Written by the Welltory science team Data analysis by the Welltory data team Reviewed by Anna Elitzur, MD

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data